部分募集资金用途与招股书披露不一致，东亚药业遭责令改正

Core Points - East Asia Pharmaceutical (605177) received a corrective measure order from the Zhejiang Securities Regulatory Bureau due to discrepancies in the use of raised funds compared to the disclosures in the initial public offering prospectus [1] - The Zhejiang Securities Regulatory Bureau found that the company did not timely fulfill the review procedures and that the information disclosure regarding the storage and actual use of raised funds was inaccurate [1] - As a result, the Zhejiang Securities Regulatory Bureau decided to implement corrective supervision measures and record this in the securities and futures market integrity file [1]